P3.01-100 Risk of Gastrointestinal and Hepatic Toxicities in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Osimertinib

Journal of Thoracic Oncology- United States

doi 10.1016/j.jtho.2018.08.1660

Full Text

Abstract

Available in

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Y. Vorakunthada

Publisher

Elsevier BV

Related search

P3.01-36 Prognostic Factors in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinical Modality of Resistance and Subsequent Management of Patients With Advanced Non-Small Cell Lung Cancer Failing Treatment With Osimertinib

Targeted Oncology

Cancer Research

English

P3.01-61 EGFR and KRAS Mutational Status and Significance in Greek Patients With Advanced Non Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer With Osimertinib

Clinical Cancer Research

Cancer Research

English

P3.01-64 Preliminary Data of Diverse Therapies in Patients With Advanced Non–Small-Cell Lung Cancer Harbouring RET-Rearrangement

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-11 Depression and Inflammation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Circadian Function in Patients With Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer

Cancer Research

English

P3.01-31 Prognostic Factors in Patients With Resected Pathological N2 Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Predictive Factors Associated With Prolonged Survival in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Gefitinib

British Journal of Cancer

Cancer Research

English